Newsletters - Dec 2001 - Jan 2002

Newsletters - Dec 2001 - Jan 2002

The diverse health benefits of the "curry spice" curcumin are well documented. Valued as an antioxidant and anti-inflammatory agent, curcumin is currently being tested as an anti-cancer drug by the NIH.

Extracted from the roots of Curcuma longa (turmeric), natural "curcumin" is essentially a mixture of three related compounds; curcumin, demethoxycurcumin and bisdemethoxycurcumin, collectively termed "curcuminoids".

A recent study provided clues to earlier observations that elderly people living in villages in India appeared to have the lowest incidence of Alzheimer's disease globally. Only 1% of those aged 65 and older experienced the gradual erosion of memory and cognition, characteristic of the disease.

Alzheimer's disease is characterized by the build up of beta-amyloid protein plaques in the brain, that are believed to be responsible for the decline in memory, as they clog the synapses that connect individual brain cells. Many of the destructive effects of beta-amyloid protein are reported to arise through oxidative damage and inflammation.

Researchers from the University of California1, Los Angeles, reported that diets rich in curcumin inhibited the development of beta-amyloid plaques in experimental models of Alzheimer's disease, as observed in middle-aged and aged rats. The researchers also speculated that compounds such as vanillin, zingerone and rosmarinic acid, with chemical structures similar to curcumin, may manifest similar effects.

In this context, another group of researchers2 reported that N-Acetylcysteine, an antioxidant compound, also had beneficial effects on Alzheimer's disease patients, presumably through the reduction of oxidative stress.

Sabinsa Corporation supplies Curcumin C3Complex? (a standardized extract from Curcuma longa roots containing a minimum of 95% curcuminoids) as well as N-Acetylcysteine.

References: 1. Frautschy S. Findings presented at the Annual Meeting of the Society of Neurology, November 2001 as reported by Reuters Health, Nov. 15, 2001*. 2. Adair, J.C. et al. (2001) Neurology 57: 1515-7.

The researchers used Curcumin C3Complex (a registered trademark of Sabinsa Corporation)

    VISIT US

  • Sabinsa Europe GmbH
    Monzastrasse 4
    63225 Langen
    Germany

  • +49 6103 270 11 11
  • +49 6103 270 11 27
  • info@sabinsa.eu

CERTIFICATES

Certificate Logos Certificate Logos
Certificate Logos Certificate Logos

CONTACT US

Disclaimer

Please note that this website and information provided herein is not for final consumers of a finished food, beverage, dietary supplement product or cosmetic product, as the information contained herein does not refer to finished products for consumers.

The information provided on the website is intended only for producers of finished food, beverage, dietary supplement and cosmetic product.

The statements related to ingredients on the website, have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease.

The website and information herein are available in various countries across the world, and hence statements or product information including its classification may not be applicable in your country.

Information and statements provided on the website, shall not be construed as license to practice, or recommendations to infringe, any patents or other intellectual property rights of Sabinsa and others.

By browsing further, You understand the above terms.